About Kadmon (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
Industry, Sector and Symbol
Trailing P/E Ratio-2.95973154362416
Forward P/E Ratio-3.96
Sales & Book Value
Annual Sales$12.26 million
Price / Sales28.22
Price / CashN/A
Book Value($0.49) per share
Price / Book-8.98
Return on EquityN/A
Return on Assets-110.26%
Kadmon (NYSE:KDMN) Frequently Asked Questions
What is Kadmon's stock symbol?
Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."
How were Kadmon's earnings last quarter?
Kadmon Holdings Inc (NYSE:KDMN) issued its earnings results on Tuesday, March, 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.12. The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $3.07 million. The company's quarterly revenue was down 65.1% on a year-over-year basis. During the same period last year, the business earned ($0.50) EPS. View Kadmon's Earnings History.
Where is Kadmon's stock going? Where will Kadmon's stock price be in 2018?
5 Wall Street analysts have issued 1 year price targets for Kadmon's shares. Their predictions range from $3.00 to $25.00. On average, they expect Kadmon's share price to reach $11.40 in the next twelve months. View Analyst Ratings for Kadmon.
Who are some of Kadmon's key competitors?
Some companies that are related to Kadmon include Rocket Pharmaceuticals (RCKT), Sorrento Therapeutics (SRNE), Abeona Therapeutics (ABEO), AC Immune (ACIU), Uniqure (QURE), Odonate Therapeutics (ODT), Endocyte (ECYT), Dicerna Pharmaceuticals (DRNA), ZIOPHARM Oncology (ZIOP), Oxford Biomedica (OXBDF), Lannett (LCI), Arrowhead Pharmaceuticals (ARWR), Fate Therapeutics (FATE), Rigel Pharmaceuticals (RIGL), Mesoblast (MESO), Progenics Pharmaceuticals (PGNX), BeyondSpring (BYSI) and Rhythm Pharmaceuticals (RYTM).
When did Kadmon IPO?
(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Has Kadmon been receiving favorable news coverage?
News articles about KDMN stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kadmon earned a daily sentiment score of 0.04 on Accern's scale. They also gave news stories about the company an impact score of 47.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Kadmon's major shareholders?
Kadmon's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Goldentree Asset Management LP (2.05%), Crestline Management LP (0.71%), Linden Advisors LP (0.67%), AE Wealth Management LLC (0.66%), Geode Capital Management LLC (0.59%) and Millennium Management LLC (0.40%). Company insiders that own Kadmon stock include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Institutional Ownership Trends for Kadmon.
Which institutional investors are selling Kadmon stock?
KDMN stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Linden Advisors LP, Millennium Management LLC and Crestline Management LP. View Insider Buying and Selling for Kadmon.
Which institutional investors are buying Kadmon stock?
KDMN stock was bought by a variety of institutional investors in the last quarter, including Goldentree Asset Management LP, Geode Capital Management LLC, Spark Investment Management LLC, Sawtooth Solutions LLC, AE Wealth Management LLC, BlackRock Inc., BlueCrest Capital Management Ltd and Wells Fargo & Company MN. Company insiders that have bought Kadmon stock in the last two years include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Insider Buying and Selling for Kadmon.
How do I buy shares of Kadmon?
Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon's stock price today?
One share of KDMN stock can currently be purchased for approximately $4.40.
How big of a company is Kadmon?
Kadmon has a market capitalization of $333.45 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Kadmon employs 101 workers across the globe.
How can I contact Kadmon?
Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]
MarketBeat Community Rating for Kadmon (KDMN)MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kadmon (NYSE:KDMN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Buy|
|Consensus Rating Score: ||2.40||2.40||2.25||2.67|
|Ratings Breakdown: ||1 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$11.40||$11.40||$9.75||$9.85|
|Price Target Upside: ||159.09% upside||146.22% upside||172.35% upside||322.75% upside|
Kadmon (NYSE:KDMN) Consensus Price Target History
Kadmon (NYSE:KDMN) Analyst Ratings History
(Data available from 3/21/2016 forward)
Kadmon (NYSE:KDMN) Earnings History and Estimates Chart
Kadmon (NYSE KDMN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/6/2018||Q4 2017||($0.36)||($0.24)||$3.07 million||$1.50 million||View||N/A|
|11/9/2017||Q3 2017||($0.38)||($0.42)||$5.69 million||$2.28 million||View||N/A|
|8/3/2017||Q2 2017||($0.49)||($0.44)||$3.46 million||$3.00 million||View||N/A|
|5/15/2017||Q1 2017||($0.52)||($0.39)||$4.25 million||$5.60 million||View||N/A|
|3/22/2017||Q4 2016||($0.71)||($0.50)||$4.50 million||$4.28 million||View||N/A|
|11/9/2016||Q3 2016||($0.40)||($4.23)||$3.90 million||$5.70 million||View||N/A|
|9/7/2016||Q2 2016||($0.88)||($4.42)||$6.48 million||$6.42 million||View||N/A|
Kadmon (NYSE:KDMN) Earnings Estimates
2018 EPS Consensus Estimate: ($0.94)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Kadmon (NYSE:KDMN)
No dividend announcements for this company have been tracked by MarketBeat.com
Kadmon (NYSE KDMN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.41%
Institutional Ownership Percentage: 61.71%
Kadmon (NYSE KDMN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/6/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||302,950||$2.73||$827,053.50|| |
|8/10/2017||Harlan Waksal||CEO||Buy||5,000||$2.27||$11,350.00||110,747|| |
|8/8/2017||Eugene Bauer||Director||Buy||5,000||$2.36||$11,800.00||1,716|| |
|8/8/2017||Harlan Waksal||CEO||Buy||3,707||$2.34||$8,674.38||105,747|| |
|8/8/2017||Steven N. Gordon||VP||Buy||1,000||$2.47||$2,470.00|| |
|7/31/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||349,661||$2.60||$909,118.60|| |
|7/11/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||34,462||$3.69||$127,164.78|| |
|6/29/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||64,375||$4.04||$260,075.00|| |
|6/27/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||108,827||$3.69||$401,571.63|| |
|6/26/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||515,643||$3.51||$1,809,906.93|| |
|6/22/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||767,363||$3.50||$2,685,770.50|| |
|3/13/2017||Daniel S Loeb||Major Shareholder||Buy||1,488,095||$3.36||$4,999,999.20|| |
|11/16/2016||Harlan Waksal||CEO||Buy||2,000||$6.37||$12,740.00||102,040|| |
|11/14/2016||Harlan Waksal||CEO||Buy||2,000||$6.79||$13,580.00||100,040|| |
|11/11/2016||Konstantin Poukalov||CFO||Buy||4,000||$5.81||$23,240.00||1,000|| |
|9/14/2016||Daniel S Loeb||Major Shareholder||Buy||19,611||$7.79||$152,769.69|| |
|9/13/2016||Daniel S Loeb||Major Shareholder||Buy||68,654||$8.33||$571,887.82|| |
|9/6/2016||Daniel S Loeb||Major Shareholder||Buy||81,781||$9.39||$767,923.59|| |
|8/26/2016||Daniel S Loeb||Major Shareholder||Buy||32,916||$9.98||$328,501.68|| |
|8/22/2016||Daniel S Loeb||Major Shareholder||Buy||11,305||$10.00||$113,050.00|| |
|8/15/2016||Daniel S Loeb||Major Shareholder||Buy||6,010||$9.95||$59,799.50|| |
|8/12/2016||Daniel S Loeb||Major Shareholder||Buy||87,529||$9.98||$873,539.42|| |
|8/5/2016||Daniel S Loeb||Major Shareholder||Buy||66,828||$9.94||$664,270.32|| |
|8/3/2016||Daniel S Loeb||Major Shareholder||Buy||1,431,996||$11.35||$16,253,154.60|| |
|8/1/2016||Goldentree Asset Management Lp||Major Shareholder||Buy||208,333||$12.00||$2,499,996.00|| |
|7/28/2016||Bart M Schwartz||Director||Buy||2,000||$9.77||$19,540.00||26,211|| |
Kadmon (NYSE KDMN) News Headlines
|Kadmon (KDMN) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - March 10 at 5:09 PM
|Kadmon (KDMN) Earns "Buy" Rating from HC Wainwright|
www.americanbankingnews.com - March 9 at 10:14 PM
|Kadmon Holdings Inc Expected to Earn Q1 2018 Earnings of ($0.23) Per Share (KDMN)|
www.americanbankingnews.com - March 9 at 7:54 AM
|Kadmon Reports Upcoming Milestones and Fourth Quarter and Full ... - Business Wire (press release)|
www.businesswire.com - March 7 at 5:12 PM
|Kadmon (KDMN) Releases Earnings Results|
www.americanbankingnews.com - March 6 at 9:12 PM
|Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - March 6 at 4:46 PM
|$3.72 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter|
www.americanbankingnews.com - March 6 at 8:58 AM
|Kadmon Holdings Inc (KDMN) Expected to Post Earnings of -$0.34 Per Share|
www.americanbankingnews.com - March 4 at 3:14 AM
|Kadmon Holdings Inc (KDMN) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - February 27 at 7:28 PM
|Wired News – Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem Meetings|
finance.yahoo.com - February 26 at 9:26 AM
|Kadmon (KDMN) Reports Updated Positive Results from Phase 2 Study of KD025 in cGVHD - StreetInsider.com|
www.streetinsider.com - February 25 at 5:06 PM
|Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD|
finance.yahoo.com - February 23 at 9:27 AM
|Kadmon (KDMN) PT Raised to $16.00 at Jefferies Group|
www.americanbankingnews.com - February 18 at 8:10 PM
|Kadmon Holdings Inc to Post FY2021 Earnings of ($2.83) Per Share, Jefferies Group Forecasts (KDMN)|
www.americanbankingnews.com - February 15 at 4:10 PM
|-$0.34 EPS Expected for Kadmon Holdings Inc (KDMN) This Quarter|
www.americanbankingnews.com - February 15 at 11:10 AM
|Kadmon (KDMN) Reports Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis|
www.streetinsider.com - February 14 at 9:07 AM
|Why Molina Healthcare, Brighthouse Financial, and Kadmon Holdings Slumped Today|
finance.yahoo.com - February 14 at 9:07 AM
|Why Karmon's "Positive" Data Turned Into a 21% Decline|
finance.yahoo.com - February 14 at 9:07 AM
|Vertex Pharmaceuticals, Kadmon Holdings Are Early Week Biotech Movers|
finance.yahoo.com - February 13 at 4:28 PM
|Kadmon (KDMN) Receives "Positive" Rating from Piper Jaffray Companies|
www.americanbankingnews.com - February 13 at 11:12 AM
|BRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis|
www.reuters.com - February 13 at 9:05 AM
|After-Hours Stock Movers 02/12: (KDMN) (VIPS) (RNG) Higher; (HMNY) (AFMD) (moh) Lower (more...)|
www.streetinsider.com - February 13 at 9:05 AM
|Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF|
finance.yahoo.com - February 13 at 9:05 AM
|Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis|
finance.yahoo.com - February 12 at 4:34 PM
|Major Biopharma Catalysts on February’s FDA Calendar|
247wallst.com - February 3 at 9:01 AM
|Kadmon Holdings Inc (KDMN) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - February 2 at 7:22 PM
|Kadmon Holdings Inc (KDMN) to Post FY2022 Earnings of ($1.58) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - January 29 at 9:10 AM
|Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3% - Nasdaq|
www.nasdaq.com - January 15 at 4:13 PM
|Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%|
finance.yahoo.com - January 15 at 10:33 AM
|Kadmon (KDMN) Lifted to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - January 14 at 8:10 PM
|Reviewing Alimera Sciences (ALIM) and Kadmon (KDMN)|
www.americanbankingnews.com - January 14 at 7:34 AM
|Kadmon Holdings Inc (KDMN) Expected to Announce Earnings of -$0.34 Per Share|
www.americanbankingnews.com - January 12 at 1:04 PM
|Kadmon Holdings Inc (KDMN) Given Consensus Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - January 8 at 10:02 PM
|KDMN And 10 Other Biotech Stocks You Should Watch This Month|
www.nasdaq.com - January 2 at 4:51 PM
|$4.07 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter|
www.americanbankingnews.com - December 28 at 2:12 AM
|Kadmon Holdings Inc (KDMN) to Post FY2017 Earnings of ($1.73) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - December 25 at 2:28 AM
|Financial Analysis: Novus Therapeutics (NVUS) & Kadmon (KDMN)|
www.americanbankingnews.com - December 23 at 3:07 AM
|ETFs with exposure to Kadmon Holdings, Inc. : December 20, 2017|
finance.yahoo.com - December 20 at 4:10 PM
|Syndax Pharmaceuticals (SNDX) versus Kadmon (KDMN) Financial Analysis|
www.americanbankingnews.com - December 20 at 11:28 AM
|Kadmon (KDMN) Stock Rating Reaffirmed by HC Wainwright|
www.americanbankingnews.com - December 15 at 2:56 PM
|Kadmon Holdings, Inc. (KDMN) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - December 14 at 11:58 PM
|Kadmon (KDMN) & The Competition Head to Head Review|
www.americanbankingnews.com - December 14 at 7:16 AM
|Kadmon (KDMN) versus Its Peers Critical Comparison|
www.americanbankingnews.com - December 12 at 11:07 AM
|Head-To-Head Survey: Kadmon (KDMN) & Its Rivals|
www.americanbankingnews.com - December 12 at 7:56 AM
|Kadmon (KDMN) Announces Updated Positive Phase 2 Data on KD025 in cGVHD - StreetInsider.com|
www.streetinsider.com - December 11 at 11:27 AM
|Zacks: Analysts Expect Kadmon Holdings, Inc. (KDMN) Will Post Quarterly Sales of $4.07 Million|
www.americanbankingnews.com - December 11 at 10:52 AM
|Kadmon (KDMN) versus Its Peers Financial Contrast|
www.americanbankingnews.com - December 10 at 11:32 PM
|Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting|
finance.yahoo.com - December 10 at 10:34 AM
|-$0.34 EPS Expected for Kadmon Holdings, Inc. (KDMN) This Quarter|
www.americanbankingnews.com - December 9 at 9:30 AM
|Kadmon (KDMN) & Its Rivals Critical Review|
www.americanbankingnews.com - December 5 at 3:32 AM
Kadmon (NYSE:KDMN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kadmon (NYSE:KDMN) Income Statement, Balance Sheet and Cash Flow Statement
Kadmon (NYSE KDMN) Stock Chart for Wednesday, March, 21, 2018